Research Article - Biomedical Research (2017) Volume 28, Issue 14
Observation of clinical effect of aspirin combined with oxiracetam in vascular cognitive impairment
Objective: This paper aims to discuss the clinical effect of aspirin combined with oxiracetam in vascular cognitive impairment.
Method: A total of 100 vascular cognitive impairment patients who were treated in hospitals from Apr 2016-2017 were collected and divided randomly into observation (n=50) and control groups (n=50). The control group was treated with aspirin, whereas the observation group was treated with aspirin combined with oxiracetam. The scores of cognitive impairment grade (MMSE) and activities of daily living (ADL) of the two groups before and after the treatment were observed.
Results: After a four-week treatment, the total clinical rate of the observation group was 90.0%, which was significantly higher than that (68.0%) of the control group (P<0.05). Before the treatment, the ADL and MMSE of the two groups had no statistical significant difference (P<0.05). After a four-week treatment, the ADL score of the observation group was 30.64 ± 2.67, which was significantly lower than that of the control group (39.11 ± 3.63). The MMSE score of the observation group was 24.32 ± 2.24, which was significantly higher than that (20.14 ± 2.15) of the control group (P<0.05).
Conclusions: Aspirin therapy combined with oxiracetam can enhance the activities of daily living, relieve hypomnesia, and significantly increase the total clinical effects of vascular cognitive impairment patients.Author(s): Zhi-Long Yang, Jian Wu, Kai-Hua Jiang, Shi-Ying Sheng, Xuan Dong